Chemix

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Chemix

Quick Facts

Property Description
Active ingredient Sulfamethoxazole & Trimethoprim
Form Tablets, Oral Suspension, Solution for Injection
Pharmacological class Antibiotic; Anti-infective agent
Common use To eliminate systemic bacterial infections
Origin Synthetic drug

Chemix: What Type of Medicine Is It?

Chemix is a trade name for the powerful synthetic drug entity known generically as Co-trimoxazole (or Co-trimazine), which functions as a broad-spectrum antibiotic and anti-infective agent. This medicine is clinically recognized as a crucial therapeutic option against various infections. This drug is distinctive as a Fixed-Dose Combination (FDC) product, intentionally composed of two distinct active chemicals. The FDC nature of Chemix sets it apart from single-agent treatments, designed to provide a more robust and decisive approach against systemic bacterial infections. It is prepared for both oral and intravenous administration in common dosage forms including tablets and oral suspension.

Composition and Synergistic Action

Chemix is fundamentally made up of two active ingredients: Sulfamethoxazole (SMX) and Trimethoprim (TMP), which together achieve a significantly enhanced medicinal effect through synergism. Sulfamethoxazole is categorized as a sulfonamide antibacterial, while Trimethoprim belongs to the diaminopyrimidine folate antagonist class. The critical feature of this pairing is its synergistic bactericidal activity, meaning the components work together to kill susceptible organisms with greater potency than either component could achieve alone. This unique chemical partnership ensures a comprehensive and highly effective attack on pathogens by blocking sequential steps in their metabolic pathway, a mechanism researched and confirmed in clinical settings.

General Purpose of This Fixed-Dose Combination

The general therapeutic purpose of this Fixed-Dose Combination is to eliminate or control a wide range of systemic bacterial infections throughout the body, such as complicated urinary tract infections, a typical use scenario for this drug class. The synergistic action, which involves the sequential inhibition of microbial folic acid synthesis (vital for bacterial growth), is the underlying principle ensuring its broad-spectrum efficacy. This dual mechanism is crucial because it not only targets a wider variety of organisms but also aids in overcoming microbial defenses, helping to reduce the potential for microbial resistance during the course of treatment.

What side effects are possible with Chemix?

Possible Side Effects and Safety Information

The safety profile of Chemix (Co-trimoxazole) is documented in official regulatory sources, which classify adverse reactions based on their expected frequency and the body system affected. These regulatory classifications utilize a standardized framework ranging from Very Common to Very Rare.

Documented Adverse Reactions and Frequency

Adverse effects commonly affect the gastrointestinal system and the skin. For instance, nausea, diarrhoea, and headache are generally classified as Common in regulatory labeling. The electrolyte imbalance hyperkalaemia (high potassium) is officially listed as a Very Common adverse reaction. Other documented system-organ classes involved include the Blood and Lymphatic System and Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Constraints

Although rare, official documents highlight the risk of Very Rare but serious adverse reactions, which include severe cutaneous events such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as blood disorders like agranulocytosis and aplastic anaemia. These severe events are officially noted to have the highest risk of occurrence within the first weeks of treatment.

Specific safety constraints are placed on the use of Chemix. The medicine is contraindicated in infants under two months of age and in patients with documented severe hepatic damage or severe renal insufficiency. Furthermore, regulatory information notes that older adults are generally more susceptible to adverse effects, especially if pre-existing renal impairment or folate deficiency is present. Adequate fluid intake is noted in the labeling to help mitigate the risk of crystalluria.

Overdose and Emergency Response

Overdose and when to seek help

The following outlines the officially documented clinical and emergency information regarding overdosage of Chemix (Co-trimoxazole), as stated in governmental regulatory sources.

Overdosage may present acutely with severe Gastrointestinal symptoms such as Nausea, Vomiting, and Anorexia, alongside signs of Central Nervous System (CNS) depression, including Dizziness, Confusion, and Drowsiness. Severe acute overexposure may escalate to loss of consciousness or seizures.


Serious Manifestations and Required Actions

The most serious outcomes documented in regulatory labeling include severe Blood Dyscrasias (e.g., bone marrow depression), Megaloblastic Anemia from chronic high-dose exposure, and significant Electrolyte Imbalances (such as Hyperkalemia). Crystalluria and Hematuria are also noted physiological findings.

Immediate medical attention is required for any suspected overdosage. Regulators explicitly state that emergency services must be contacted immediately if the individual is unconscious, has trouble breathing, or experiences a seizure following exposure. Management is symptomatic and supportive, often requiring laboratory monitoring of blood counts and electrolytes, and potentially the administration of Folinic Acid to manage the anti-folate effects on the bone marrow.

Therapeutic Uses of Chemix

What Chemix Treats: Main Uses and Benefits

Chemix is commonly used across therapeutic domains where additional symptomatic support is needed. It is primarily used for managing symptoms related to physical discomfort and systemic imbalance. It is used for easing symptoms associated with acute or episodic changes, playing a role in managing symptoms that create noticeable physiological strain, such as a high temperature.

Chemix is applied in scenarios where short-term symptomatic assistance is needed to manage a wide range of common aches. This helps address symptom clusters that may become intense or disruptive. This commonly involves symptoms related to inflammatory or irritative states, such as headache, toothache, various muscular aches, and discomfort associated with colds and flu. This provides support that helps ease the overall symptom burden and may assist patients in coping more steadily with symptom fluctuations.

Quick Fact: Relief for Physical Discomfort and Systemic Imbalance

Regulatory References

  1. TGA Over-the-Counter Monograph

Eligibility and Restrictions for Use

Who Can and Cannot Use Chemix?

The official regulatory profile for Chemix (Co-trimoxazole, Sulfamethoxazole & Trimethoprim) defines strict population eligibility, primarily classifying individuals as allowed, restricted, or absolutely contraindicated based on age, physiological status, and underlying conditions.

Populations for Whom Use is Contraindicated

Chemix must not be used by individuals with the following conditions, as established by governmental regulatory bodies:

  • Hypersensitivity: Known allergy to Sulfamethoxazole, Trimethoprim, or any sulfonamide-derived drug.
  • Severe Organ Dysfunction: Patients with marked hepatic damage or severe renal insufficiency (e.g., Creatinine Clearance less than 15 mL/min).
  • Hematologic/Metabolic Issues: Documented megaloblastic anemia due to folate deficiency, acute porphyria, or a history of drug-induced immune thrombocytopenia.
  • Co-administered Drugs: Patients currently receiving the antiarrhythmic medicine Dofetilide.

Age-Specific Eligibility

Age Group Regulatory Status
Infants Contraindicated in those less than 2 months of age.
Older Adults Use requires particular care due to potential susceptibility to adverse reactions.

Other Restrictions

The medicine is contraindicated for use in pregnant patients at term and in nursing mothers. Use requires caution in patients with conditions like Glucose-6-phosphate dehydrogenase (G6PD) deficiency or severe allergies/bronchial asthma.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Chemix (Sulfamethoxazole & Trimethoprim) is primarily structured by pharmacokinetic alterations and pharmacodynamic reinforcement risks, as documented in official regulatory labeling.

Contraindicated and Clinically Significant Combinations

Classification Interacting Substance Official Interaction Pattern/Outcome
Contraindicated Dofetilide Co-administration is prohibited due to risk of life-threatening cardiac events.
Avoided Leucovorin (adjunctive) Avoid concurrent use for Pneumocystis jirovecii pneumonia due to documented increased mortality.
Clinically Significant Warfarin Potentiation of anticoagulant activity via stereo-selective inhibition of its metabolism.

Exposure and Pharmacodynamic Effects

Regulatory documents detail interactions that modify drug exposure or create additive effects. Co-administration prolongs the half-life of phenytoin and causes a documented 40% increase in lamivudine exposure. Furthermore, there is an additive risk of hyperkalaemia when Chemix is combined with ACE inhibitors or potassium-sparing diuretics. The drug also interacts with OCT2 substrates such as amantadine and metformin by affecting their renal clearance. Risk is heightened in specific populations; for example, co-administration with thiazide diuretics carries an increased risk of thrombocytopenia specifically in elderly patients. The labeling also notes that concurrent use with alcohol/ethanol is associated with documented unpleasant systemic side effects.

Mechanism of Action

Dual Blockade of Folic Acid Synthesis

Chemix works by executing a precise sequential inhibition against two key enzymes in the susceptible pathogen's metabolic pathway: Dihydropteroate Synthase (DHPS) and Dihydrofolate Reductase (DHFR). The initial block by Sulfamethoxazole and the subsequent block by Trimethoprim causes the microbial cell to be unable to synthesize the vital cofactor Tetrahydrofolic Acid ( FH4).


Synergistic Action and Microbial Cell Death

The simultaneous targeting of two consecutive steps leads to a synergistic bactericidal effect, where the combined potency against the pathogen is greater than the additive effect of either component. This metabolic disruption leads to the cessation of the pathogen's DNA, RNA, and protein synthesis, resulting in a reduction of the systemic bacterial load.


Mechanism Specificity and Selectivity

The drug's mechanism is highly selective because it targets a pathway step (DHPS) that is completely absent in human cells, which acquire folate from their diet. This ensures that the severe metabolic disruption is largely confined to the invading pathogens, limiting the impact on the host’s cellular machinery. However, the mechanism is constrained in environments where high concentrations of PABA may locally override the initial block, weakening the enzyme inhibition.

Dosage and Administration Information

How to Use Chemix

Chemix (Co-trimoxazole) is administered via two approved routes: oral (using tablets or oral suspension) and intravenous (IV) infusion. The medicine is generally prescribed on a twice-daily (every 12 hours) schedule for most acute infections, with treatment courses typically ranging from 5 to 14 days. For more specialized treatments, such as Pneumocystis Jirovecii Pneumonia (PJP), the regimen requires the total daily dose to be divided and administered every 6 to 8 hours for a longer duration.

The standard adult dose is 800 mg of Sulfamethoxazole (SMX) and 160 mg of Trimethoprim (TMP) per dose. This regimen requires mandatory adjustment for specific populations. Pediatric patients 2 months of age and older are dosed according to body weight. For adults with moderate renal impairment (Creatinine Clearance (CrCl) 15 to 30 mL/min), the standard dose is generally reduced by 50%.

The oral forms can be taken with or without food; however, all patients must maintain adequate fluid intake throughout therapy to mitigate procedural constraints. The solution for injection is strictly for IV infusion and must be diluted prior to use, then administered slowly over 60 to 90 minutes to ensure correct delivery, with rapid injection being strictly prohibited. If a dose is missed, it should be taken as soon as remembered, but patients must never take a double dose to compensate for the lapse.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Chemix

The evidence for Chemix (Sulfamethoxazole & Trimethoprim) has been derived from a substantial body of research, including numerous Randomized Controlled Trials (RCTs) and meta-analyses that explore the medicine's role in various bacterial infections. Research has focused on monitoring specific outcomes, such as the clearance of bacteria and measurements of infection-related symptoms, across defined time intervals. Findings describe patterns observed in the studies related to how symptoms evolved, but research does not determine whether an individual will respond similarly.


Evidence for Use in Urinary Tract Infections (UTIs)

Studies examining Chemix for Urinary Tract Infections (UTIs), which are conditions characterized by fluctuating or episodic manifestations, typically involve short-term Randomized Controlled Trials and systematic comparisons with other antimicrobial agents. These studies were conducted on different patient populations, including adult women with uncomplicated UTIs and patient cohorts with more complicated or severe urinary tract infections.

Research primarily examined outcomes such as the clinical assessment of infection signs and symptoms and microbiological eradication, which is the laboratory-measured clearance of the specific bacteria causing the infection. Trial data described patterns observed in the studies, reporting success measurements related to both clinical status and laboratory findings.


Evidence for Use in Pneumocystis Jirovecii Pneumonia (PJP)

The research for Pneumocystis Jirovecii Pneumonia (PJP) has been evaluated in both RCTs and large observational studies. These studies explored two main scenarios: the active treatment of PJP and the monitoring of prevention outcomes (prophylaxis). Research was primarily conducted in immunosuppressed patient populations, such as adults and children with HIV. The key outcomes monitored included measurements of survival rates and the tracking of occurrence of PJP episodes.


Long-Term Evidence and Research Uncertainty

Most research focuses on short-term outcomes that reflect the immediate course of acute infection treatment. However, extended research efforts, particularly for PJP prophylaxis, have monitored outcomes over prolonged time intervals (sometimes years). For most other indications, there is limited information for long-term outcomes to fully characterize the effects beyond the short-term clearance of the acute infection.

A major research limitation is the increasing variability of microbial resistance to the drug components across different regions. This means the applicability of measured outcomes is dependent on local bacterial patterns. Data for certain groups, such as very young children and patients with complex underlying diseases, remain insufficient.

Key Studies & References

  1. Trimethoprim Sulfamethoxazole - StatPearls (Overview of FDA-Approved Indications and Dosing)
  2. Low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia in HIV-uninfected patients: a systematic review and meta-analysis
  3. Management of acute otitis media (Systematic Review comparing regimens)

Frequently Asked Questions (FAQ)

Common questions about Chemix (FAQ)

Q: Do the side effects of Chemix usually go away after a few weeks?

The official labeling does not give a specific timeframe for how long common side effects typically last. Regulatory information focuses on warning patients that if they develop signs of a serious reaction, such as a severe rash, it is recommended to contact a healthcare professional immediately. It is also noted that a severe intestinal infection (C. difficile-associated diarrhoea) can sometimes occur weeks to months after Chemix treatment has ended.


Q: Is it normal to feel tired when starting Chemix?

Yes, feeling tired, which is medically referred to as fatigue or asthenia, is listed among the possible side effects in the official prescribing information for Chemix. This indicates that fatigue may be a documented reaction during the course of treatment.


Q: Can Chemix affect my sleep?

Official reports from clinical trials and post-marketing experience indicate that disorders of the nervous system are possible side effects. These disorders include insomnia, which is a documented type of trouble sleeping that may be associated with the medicine.


Q: Are there any specific vitamins or supplements that interact with Chemix?

Chemix is known to act on the body's folic acid pathways. Official information indicates that folic acid supplementation may be administered without interfering with the drug’s action in most circumstances. Official documents also mention interactions with supplements like Vitamin D and note the risk of additive effects when combining Chemix with potassium supplements.


Q: Can I drink coffee while taking Chemix?

Official regulatory labeling primarily provides warnings regarding the consumption of alcohol. While there is no specific prohibition on coffee or caffeine, general healthcare guidance notes that limiting intake may be relevant due to caffeine’s diuretic effect. This is because patients using Chemix are advised to maintain adequate fluid intake throughout therapy.


Q: Is Chemix a commonly prescribed medicine?

Yes, evidence indicates that the active ingredients in Chemix (Trimethoprim/Sulfamethoxazole) are considered crucial on a global scale. This is evidenced by their inclusion on the World Health Organization’s List of Essential Medicines. In many regulatory regions, Chemix is reported as one of the most frequently prescribed generic antibiotic combinations.


Q: Is Chemix known to be habit-forming or addictive?

Regulatory authorities have not classified Chemix (Co-trimoxazole) as a controlled substance. Official information indicates the medicine is not known to be habit-forming or addictive.


Q: What should I do if a side effect from Chemix feels unusual?

Regulatory guidance advises patients to monitor their reaction to the medicine closely. If any signs of a serious adverse reaction occur, particularly a severe rash or allergic symptoms, regulatory documents describe that stopping the medicine is recommended and suggest seeking medical attention.


Q: Will Chemix interfere with my ability to drive or operate machinery?

Official documentation states that the effects of Chemix on the ability to drive or operate machinery have not been specifically tested in clinical studies. Regulatory information suggests exercising caution and self-monitoring for side effects such as dizziness.


Q: Can the effectiveness of Chemix be reduced by certain foods?

Chemix can be taken either with food or on an empty stomach, and this administration condition is noted in official documents. However, it is noted that consuming large amounts of potassium-rich foods or supplements may increase the risk of the very common adverse reaction of hyperkalaemia (high potassium).


Q: Can Chemix affect the results of lab tests?

Yes. Official regulatory labeling indicates that monitoring of blood counts and certain chemical levels may be necessary during treatment. This advice is provided because of the documented risk of changes to blood components and kidney function, confirming that the medicine can influence lab results.


Q: Is it necessary to finish the entire course of Chemix even if I feel better?

Yes. Regulatory guidelines emphasize that the entire course of therapy should be completed as directed. Stopping the medicine too early can lead to the infection returning and increases the risk of developing drug-resistant bacteria.


Q: Does Chemix have a warning about sun exposure?

Yes. Official regulatory warnings are in place regarding sun exposure and Chemix. The medicine is associated with photosensitivity (increased sensitivity to sunlight), and regulatory information suggests minimizing exposure to sunlight and utilizing protective measures, such as clothing or sunscreen.


Q: Does Chemix have any specific warnings for individuals with heart conditions?

Official documents state a strict prohibition on using Chemix with the antiarrhythmic drug Dofetilide due to the risk of severe, life-threatening heart events. While a general warning for all heart conditions is not explicitly listed, fluid balance is a critical aspect that may require monitoring.


Q: Is there a list of ingredients in Chemix besides the active one?

Yes. The official prescribing information provides a complete description of the product's composition. This includes both the active ingredients (Sulfamethoxazole and Trimethoprim) and the inactive ingredients, which are referred to as excipients, such as sodium metabisulphite or specific preservatives.


Q: Do I need a special prescription for Chemix?

Yes. Chemix (Co-trimoxazole) is regulated by governmental health authorities as a Prescription Only Medicine (POM). This means that a valid prescription from a licensed healthcare provider is required to obtain the drug in most countries.


Q: Is there a patient leaflet for Chemix I can download?

Yes. Patient Information Leaflets (PILs) or Patient Package Inserts are public documents mandated by regulatory bodies like the FDA and EMA. These documents are generally available for download on the websites of the government agencies that regulate drug safety and information.


Q: What happens if I stop taking Chemix suddenly?

Regulatory information indicates that stopping antibiotic treatment prematurely increases the likelihood of the original infection returning and promotes the development of drug-resistant bacteria. Furthermore, a severe intestinal infection, C. difficile-associated diarrhoea, can sometimes occur weeks to months after the drug is discontinued.

How should Chemix be stored and disposed of?

The official labeling dictates strict conditions for storing and handling Chemix (Co-trimoxazole) to maintain its quality.

Storage Requirements

Condition Requirement (Regulatory Basis)
Temperature Store at room temperature (e.g., below 25 C or 30 C); Do not freeze.
Protection Keep the medicine in its original container, tightly closed, and protect from light and excess moisture.
Child Safety Keep out of the sight and reach of children in a secure location.

Disposal Instructions

Do not dispose of any unused or expired Chemix by flushing it down a toilet or pouring it into a drain. The product must be disposed of only in accordance with local pharmaceutical waste regulations (e.g., drug take-back programs) to protect the environment and prevent unauthorized access.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Chemix found in:

A-Z Index: